Physician Views: Ofev approved, Esbriet label updated - what impact on IPF-treating pulmonologists in the EU5?

Physician Views: Ofev approved, Esbriet label updated - what impact on IPF-treating pulmonologists in the EU5?

Code: FW-20150201 | Published: Feb-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






The European idiopathic pulmonary fibrosis (IPF) community appears to have benefited from a number of recent developments.

Last month, Boehringer Ingelheims Ofev was approved as the second treatment for IPF in the region, while towards the end of last year, the label for Esbriet - a competing therapy already available in the region - was updated to include a mortality benefit.

Furthermore, Esbriet was integrated into the portfolio of Swiss Big Pharma player Roche last year following its acquisition of InterMune, a move that should hopefully improve patient access.

Much focus on the IPF market has been in the US where both Ofev and Esbriet were approved in the fourth quarter of 2014 (Esbriet was approved in Europe during 2011, but InterMune was required to carry out additional Phase III studies to secure US clearance).

See Physician Views Poll Results: The idiopathic pulmonary fibrosis (IPF) market - let battle commence.

However, approval of Boehringer Ingelheims drug will now intensify competition in the EU market where between 80,000 and 100,000 patients are believed to suffer from IPF.








To better ascertain how this competitive dynamic may play out, FirstWord is this week polling pulmonologists based in the EU5 markets (France, Germany, Italy, Spain and the UK) to ascertain their views towards both products. Specifically we are asking them...


- How important they consider the recent approval of a second IPF therapy in Europe to be in advancing the standard of care for this condition (i.e. in terms of clinical profile for Ofev versus Esbriet)?

- What the likelihood is that a label update for Esbriet to include polled mortality benefit will have a significantly positive impact on their usage of the drug?

- Based on clinical profile, which product - Esbriet or Ofev - they think is superior and to what extent?

- To what extent would you expect Esbriets existing position in the market to act as a barrier to uptake for nintedanib?

- How satisfied they are with patient access to IPF therapy in their domestic market?


Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord